Bavarian stock price drops despite guidance upgrade and EU monkeypox vaccine order

Looking for an explanation for why Bavarian’s newest vaccine contract hasn’t been met with market enthusiasm, one Sydbank analyst points to a generally rainy trading day.
Photo: Bavarian Nordic / PR
Photo: Bavarian Nordic / PR
by marketwire, translated by daniel pedersen

The European Union had already indicated interest in a shared purchase of vaccine doses for monkeypox, so Tuesday’s news that the EU has signed a contract shouldn’t have come as a big surprise, according to Senior Equity Analyst at Sydbank Søren Løntoft Hansen.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Photo: Mike Blake/Reuters/Ritzau Scanpix

    Gilead Sciences CMO to leave early 2025

    For subscribers

    Further reading